Prophase Labs News Today

ProPhase Labs (NASDAQ:PRPH – Get Free Report) and Panbela Therapeutics (NASDAQ:PBLA – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations. Profitability This table compares ProPhase Labs and […]

ProPhase Labs, Inc. (NASDAQ:PRPH – Get Free Report)’s stock price crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $5.08 and traded as high as $5.26. ProPhase Labs shares last traded at $5.24, with a volume of 24,833 shares traded. Analysts […]

ProPhase Labs, Inc. (NASDAQ:PRPH – Free Report) – Diamond Equity issued their Q1 2025 EPS estimates for shares of ProPhase Labs in a note issued to investors on Monday, April 22nd. Diamond Equity analyst H. Diamond forecasts that the company will post earnings per share of $0.10 for the quarter. The consensus estimate for ProPhase […]

ProPhase Labs, Inc. (NASDAQ: PRPH) saw its shares lose some strength Wednesday, as the next-generation biotech, genomics, and diagnostics company, reported its progress on the commercialization of its breakthrough BE-Smart test for esophageal cancer. ...

HC Wainwright reiterated their buy rating on shares of ProPhase Labs (NASDAQ:PRPH – Free Report) in a research note released on Wednesday morning, Benzinga reports. HC Wainwright currently has a $11.00 target price on the stock. ProPhase Labs Price Performance PRPH stock opened at $4.96 on Wednesday. The company has a fifty day moving average […]

The Global Short-Read Sequencing Industry is poised for extraordinary expansion, with a forecasted value of $6.32 billion in 2023, expected to surge to an impressive $34.4 billion by 2033. This remarkable growth reflects a substantial Compound Annual Growth Rate (CAGR) of 18.46% in short-read sequencing sales during...

ProPhase Labs, Inc. (NASDAQ: PRPH) fell Tuesday, as the company, a next generation biotech, genomics, therapeutics and diagnostics company, today reported that Jason Karkus, one of the driving forces behind ProPhase Diagnostics, becomes President of ...

ProPhase Labs, Inc. (NASDAQ:PRPH – Get Free Report) shares crossed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $5.44 and traded as low as $4.56. ProPhase Labs shares last traded at $4.73, with a volume of 29,277 shares. Wall Street Analyst […]

Operator: Good day and welcome the ProPhase Labs Incorporated Third Quarter 2023 Financial Results and Corporate Update. All participants will be in listen-only mode.